Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MRI scan · 1 trial · 1 indication
ADP, ATP, PCr, Pi, and pH will be measured during rest, anaerobic exercise and recovery to determine muscle metabolism.
| Arm | Type | Description |
|---|---|---|
| no treatment | NO_INTERVENTION | MRI scans only |
| Name | Type | Description |
|---|---|---|
| MRI scan | OTHER | MRI scan only, methodology study with no other intervention |
Inclusion Criteria: 1. Fit to safely tolerate procedures 2. Male or female between 18 and 80 years of age 3. If pre-menopausal female, non-pregnant on dipstick urinalysis 4. Subject and responsible physician agree that the subject will be able to comfortably lie in scanning position in the scanner ...
MRI scan is an investigational diagnostic imaging approach being studied for use in muscular atrophy. It is currently in Phase 1 clinical development. The drug is being evaluated for its potential role in assessing or managing muscle atrophy, though it remains investigational and has not been approved for this indication.
MRI scan is being developed by GSK plc, a global biopharmaceutical company listed on the stock exchange under the ticker GSK. The company is conducting clinical research on this asset for the treatment of muscular atrophy, with the drug currently in Phase 1 development.
MRI scan is in Phase 1 clinical development. It is an investigational drug being studied for muscular atrophy. The drug has not been approved by regulatory authorities and is still undergoing clinical trials to evaluate its safety and potential efficacy.
MRI scan has one completed clinical trial, NCT01476072, titled '31P MRS Ischaemic Exercise Optimisation and COPD'. This Phase 1 study enrolled 75 participants in the United Kingdom and included healthy volunteers. The trial was not randomized, double-blind, or biomarker-selected, and used a no-treatment controlled design.
MRI scan is the name used for this investigational asset in clinical development. No alternative names have been established for this drug in the available information. It is being studied under this name by GSK plc for the potential treatment of muscular atrophy.